Midostaurin maintenance appeared safe and was linked to a survival benefit for low- to intermediate-risk patients with FLT3-mutated acute myeloid leukemia.
Strong study results in two phase 3 clinical trials may soon change go-to care, plus a promising treatment for bladder cancer inches closer to a new indication.